Globeimmune Inc
OTC:GBIM

Watchlist Manager
Globeimmune Inc Logo
Globeimmune Inc
OTC:GBIM
Watchlist
Price: 0.0001 USD Market Closed
Market Cap: 575 USD

Globeimmune Inc
Investor Relations

GlobeImmune, Inc. is a biopharmaceutical company. The company is headquartered in Louisville, Colorado. The company went IPO on 2014-07-02. The firm is engaged in development of products for the treatment of cancer and infectious diseases. The firm provides Tarmogen platform, which activate the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells, in contrast to traditional vaccines which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. The firm's oncology product candidates include GI-6301, GI-6207 and GI-4000. The firm's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. C. Jeffrey Dekker CPA
President, Vice President of Finance, Treasurer & Secretary
No Bio Available
Dr. Richard C. Duke
Scientific Founder & Member of Scientific Advisory Board
No Bio Available
Dr. Donald Bellgrau
Scientific Founder & Chairman of The Scientific Advisory Board
No Bio Available

Contacts

Address
COLORADO
Louisville
1450 Infinite Dr
Contacts
+13036252700.0
www.globeimmune.com